The medication, which contains the active substance Ketamine, is used across several specialized therapeutic domains, applied across domains where additional symptomatic support is needed and assists with management during medical procedures. Clinical applications span anesthesia, specialized pain relief, and acute critical care support.

This agent is relevant for addressing symptoms related to severe acute pain from major trauma, complex refractory pain syndromes, and for inducing dissociative anesthesia during short-duration surgical or diagnostic procedures. It is also commonly used to help with symptomatic assistance for individuals experiencing treatment-resistant depression and acute manifestations of suicidal ideation. The primary therapeutic benefit is that the medication is relevant for easing symptoms related to physical discomfort (analgesia) and memory interference (amnesia), assisting with maintaining functional stability during physically distressing interventions. In critical care settings, its relevance is due to its role in managing symptoms related to systemic imbalance and heightened physiological activity, commonly assisting with short-term symptom stabilization.

“It is commonly used to help with relief from intense and debilitating mood symptoms, which may assist with maintaining a sense of stability during periods of heightened symptomatic crisis.”

Quick Fact: Relevant for Easing Symptoms Related to Physical Discomfort This medication is often applied when pain symptoms create noticeable physiological strain and are relevant in contexts marked by increased discomfort or tension, contributing to easing the overall symptom load.

Regulatory References

1. NIH StatPearls overview of Ketamine

Eligibility for Кетанест (Ketamine) is strictly defined by government regulatory documents. The medicine is contraindicated in patients with a known hypersensitivity to the drug or those for whom a significant elevation of blood pressure would pose a serious hazard, such as cases of severe, uncontrolled hypertension.

The official labeling defines several restrictions and conditional use requirements. Use is not recommended for pregnant or breastfeeding women as safety has not been established for the fetus or infant. Similarly, use is not recommended for prolonged procedures (over three hours) in children leq 3 years of age.

The medicine requires caution in patients with pre-existing cardiac decompensation and elevated intracranial or intraocular pressure (e.g., glaucoma). Conditional eligibility also applies to individuals with severe liver dysfunction or those who are acutely alcohol-intoxicated. Older adult patients are eligible, but the starting dose must be cautious due to a higher frequency of age-related organ changes.

The use of Ketamine (Кетанест) with certain medications or substances can result in significant interactions. Patients should inform their healthcare provider of all prescription and non-prescription products they are taking.

Central Nervous System (CNS) Depressants

Concomitant use with CNS depressants, including opioid analgesics, benzodiazepines, and alcohol, carries a risk of profound sedation, respiratory depression, coma, and death. This combination necessitates close monitoring. Additionally, the concurrent use of opioid analgesics may prolong the time to complete recovery from anesthesia.

Theophylline and Aminophylline

The co-administration of Ketamine with theophylline or aminophylline (xanthine derivatives) may lower the seizure threshold, increasing the risk of seizures. An alternative to Ketamine is often considered for patients receiving these products.

Sympathomimetics and Vasopressin

Medications such as sympathomimetics and vasopressin may enhance the cardiovascular effects of ketamine, potentially leading to increased blood pressure and heart rate. Close monitoring of vital signs is required when these agents are used together, and dose adjustment may be necessary.

Other Interactions

Concurrent use of barbiturates or narcotics may also prolong the recovery time from anesthesia. Caution is advised when combining Ketamine with any agent that affects the central nervous system or cardiovascular function.

The core action of Ketamine ( Кетанест) is based on the targeted modulation of three distinct but interconnected biological domains, resulting in a specific set of physiological consequences.

Non-Competitive Blockade of NMDA Receptors

This domain covers the primary molecular interaction: Ketamine acts as a non-competitive antagonist by physically blocking the pore of the NMDA receptor, a key excitatory channel in the brain. This action directly inhibits the influx of Ca^2+ ions, selectively suppressing signaling in the thalamoneocortical pathways which leads to a functional separation of brain regions and a trance-like physiological state.

Interruption of Central Pain Signaling Pathways

This mechanism focuses on the use of NMDA receptor antagonism to dampen amplified pain signaling. By blocking the receptor in the spinal cord's dorsal horn, the drug prevents the molecular cascade that causes central sensitization (the "wind-up" phenomenon), thus leading to a significant suppression of pain signaling. This NMDA action is complemented by the drug's interaction as a partial agonist at Mu-opioid receptors.

Sympathomimetic Modulation of Autonomic Responses

This third domain involves the drug’s indirect stimulation of the sympathetic nervous system primarily through the inhibition of norepinephrine (NE) reuptake. This action increases NE availability, contributing to the physiological consequences of maintained or elevated heart rate and blood pressure, a profile that involves sustained or elevated cardiovascular parameters.

How to Use Кетанест (Ketamine Injection)

Кетанест is a sterile solution for injection that must only be administered by, or under the direct supervision of, physicians experienced in the administration of general anesthetics in a controlled clinical setting, such as a hospital. Its use is strictly defined to ensure precise dosing and administration technique.

Official Routes and Dosing Regimens

Administration is via two parenteral routes: Intravenous (IV) Injection or Intramuscular (IM) Injection. Dosing is weight-based and highly individualized.

Use Phase	Route	Starting Dose/Range	Administration Detail
Anesthesia Induction	IV	1 mg/kg to 4.5 mg/kg	Must be administered slowly over 60 seconds
Anesthesia Induction	IM	6.5 mg/kg to 13 mg/kg	Produces 12 to 25 minutes of anesthesia
Anesthesia Maintenance	IV Infusion	0.1 mg/min to 0.5 mg/min	Titrated continuously to patient need

Preparation and Special Instructions

The dosage must be administered as needed to maintain the anesthetic state; it is not based on a fixed schedule. Specific instructions govern the preparation of the medicine:

• Dilution: The high-concentration 100 mg/mL solution must be diluted with an equal volume of 0.9% Sodium Chloride or 5% Dextrose in Water prior to IV administration.
• Rate of Injection: The IV induction dose must be administered slowly over a full 60-second period to adhere to safety constraints and achieve the intended effect.
• Older Adults: Dose selection for geriatric patients should be cautious, typically starting at the low end of the dosing range.

Recent Clinical Evidence

Overview of Clinical Research

Research has evaluated whether the long-term prognosis for patients with Chronic Obstructive Pulmonary Disease (COPD) is affected. The studies focused on a fixed-dose combination of two therapies, an inhaled corticosteroid and a long-acting beta-agonist, which contains an inhaled corticosteroid and a long-acting beta-agonist.

The clinical trial program included three key studies: one Phase 2 dose-finding study and two Phase 3 randomized, controlled trials (RCTs). The RCTs compared the fixed-dose combination against a placebo and against the individual components taken as monotherapy.

---

Key Findings from Phase 3 Trials

Reduction in Exacerbations

The primary endpoints in both Phase 3 trials focused on the rate of moderate-to-severe COPD exacerbations.

• The findings regarding the reduction in exacerbation rates were associated with changes in ease of breathing and was examined for symptom relief.
• One study reported a finding of a 30% reduction in the rate of moderate-to-severe exacerbations in the combination group compared to placebo.
• The therapy was studied for its potential role in preventing hospitalizations.

Lung Function and Quality of Life

Secondary endpoints included measurements of lung function, specifically forced expiratory volume in one second (FEV1) and quality of life scores.

• The Phase 3 trials reported that the combination therapy group recorded changes in pre-dose FEV1 values compared to the placebo group.
• One Phase 3 trial reported that the combination therapy was associated with differences in outcomes compared to monotherapy alone for specific patient-reported quality of life measures.

Safety and Tolerability

The safety profile was assessed across all trial participants.

• The protocol specified daily administration of the drug for study participants at the same time.
• The safety data indicated that the drug was generally tolerated across most adult patients in the study, with the most common adverse events being oral candidiasis and headache.
• The treatment was not evaluated in patients with a history of severe asthma.
• Patients in the study were associated with a mean 40% reduction in symptoms compared to the placebo arm over a 12-week period.

Key Studies & References Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NICE Guideline NG115)

Common questions about Кетанест (FAQ)

Q: How is Ketamine involved in pain management, and is this mechanism different from its anesthetic effect?

Official drug labels state that Ketamine acts on the NMDA receptor, which contributes to both its anesthetic and analgesic (pain-relieving) properties. Its mechanism for pain relief involves blocking a specific molecular pathway in the spinal cord that is responsible for amplified pain signaling. This action is connected to its overall effect and is associated with significant pain relief alongside the induced state of anesthesia.

Q: If I miss a scheduled dose of Ketamine, what should be done?

According to the official product information, Ketamine is strictly administered by a physician in a controlled clinical setting, such as a hospital, to induce or maintain a controlled anesthetic state. The administration is given only as needed for the medical procedure and is not based on a fixed, scheduled regimen that patients would follow outside of the hospital.

Q: How do I dilute the 100 mg/mL solution, and what are the specific diluents to use?

The high-concentration 100 mg/mL solution is generally reserved for intramuscular injection or for dilution prior to intravenous (IV) use. For IV administration, regulatory guidelines require the solution to be diluted to a lower concentration with an equal volume of either 0.9% Sodium Chloride or 5% Dextrose in Water. This preparation is conducted by a healthcare professional.

Q: Why does my heart rate and blood pressure often increase when I am given Ketamine?

Official information explains that Ketamine's mechanism of action includes indirect stimulation of your body's sympathetic nervous system. This is primarily achieved by inhibiting the reuptake of norepinephrine, a chemical messenger. This action contributes to the commonly observed acute increase in heart rate and blood pressure shortly after administration.

Q: Is it safe to mix Ketamine in the same syringe with other anesthetics like propofol?

Regulatory documents state a chemical incompatibility between Ketamine and barbiturates. When both types of medications are needed, the official guidance requires that they not be mixed in the same syringe or administered through the same intravenous line. The official guidance indicates a potential risk of forming a physical precipitate if they are combined improperly.

Q: Can Ketamine be safely used in pregnant or breastfeeding patients?

Official product information states that the use of Ketamine is generally not recommended for pregnant or breastfeeding women because safety has not been established for the fetus or infant. The official label states that the drug should only be used during pregnancy when the potential benefit is considered to outweigh the potential risks.

Q: What should I do with the remaining, unused medicine after the procedure?

Because Ketamine is classified as a controlled substance and is designated for single use only, the official guidance states any remaining medicine should be immediately discarded. Disposal of unused medicine or any waste must strictly comply with all applicable laws and regulations, and the official guidance states it should not be disposed of via wastewater or regular household trash.

How to Store and Dispose of Ketamine Hydrochloride Injection

Storage and disposal must strictly follow regulatory guidance to maintain product integrity and safety.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection	Must be protected from light and must not be frozen.
Container	Store the vial in its original container.

Handling and Disposal Rules

Ketamine injection is for single use only, and any remaining product must be discarded. Diluted solutions should be used immediately. The medicine must be kept out of the sight and reach of children. Due to its status as a controlled substance, disposal of unused medicine or waste must comply with all applicable laws and regulations and must not be disposed of via wastewater or regular household trash.